Website
News25/Ratings8
News · 26 weeks21+150%
2025-10-262026-04-19
Mix1390d
- Other7(54%)
- SEC Filings4(31%)
- Earnings2(15%)
Latest news
25 items- SECAngioDynamics Inc. filed SEC Form 8-K: Other Events8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- SECSEC Form 10-Q filed by AngioDynamics Inc.10-Q - ANGIODYNAMICS INC (0001275187) (Filer)
- SECAngioDynamics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- PRAngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued ProfitabilityMed Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted EBITDA AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Ne
- PRAngioDynamics to Present at the 25th Annual Needham Virtual Healthcare ConferenceAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the management team will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026. The Company's presentation will begin at 8:45 a.m. (ET). A live webcast of the event will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay following the event. About AngioDynamics, Inc. AngioDynamics is a leading and transformative medica
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AngioDynamics Inc.SCHEDULE 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
- PRAngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the AngioD
- PRAngioDynamics to Present at the Leerink Partners Global Healthcare ConferenceAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live webcast of the event will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay following the event. About AngioDynamics, Inc. AngioDynamics is a leading
- PRAngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation PlatformGrowing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor Types AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The expanded indications increase physician access to the NanoKnife System's irreversible electroporation (
- SECSEC Form SCHEDULE 13G filed by AngioDynamics Inc.SCHEDULE 13G - ANGIODYNAMICS INC (0001275187) (Subject)
- PRAngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism CareThe ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, and The PERT Consortium®, a leading multidisciplinary organization dedicated to improving pulmonary embolism (PE) care, today announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent PE research. Pulmonary embolism affects approximately one in 1,000 people annually1. It is estimated to contribute to more
- SECAngioDynamics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- PRAngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to AdvancePhysician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it will convene leading cardiovascular physicians and researchers at its third Cardiovascular Scientific Forum, as the Company advances multiple cardiovascular programs following recent FDA regulatory milestones into active clinical engagement. The Cardiovascular Scientific Forum is structured as a working scientific convening focused on ph
- SECAngioDynamics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- SECSEC Form 10-Q filed by AngioDynamics Inc.10-Q - ANGIODYNAMICS INC (0001275187) (Filer)
- SECAngioDynamics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- PRAngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased ProfitabilityMed Tech segment delivers fifth consecutive quarter of double-digit growth Strong adjusted EBITDA; and positive cash flow Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac 510(k) clearance, PAVE and APEX-Return IDE approvals Raised full year FY 2026 guidance for net sales and Adjusted EBITDA Jim Clemmer to retire during fiscal year 2027 as President and CEO upon appointment of successor; Board initiates comprehensive CEO search AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving
- PRAngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market open on Tuesday, January 6, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the Angio
- PRAngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceAngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:00 p.m. (PT). A live webcast of the event will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay follow
- SECAngioDynamics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- PRAngioDynamics to Participate in the UBS Global Healthcare ConferenceAngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov. 10 2025. A live webcast of the fireside chat will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay following the event. About AngioDynamics, Inc.
- INSIDERSVP, Chief Legal Officer Weiss Lawrence T bought $118,100 worth of shares (10,000 units at $11.81), increasing direct ownership by 12% to 93,597 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- SECSEC Form S-8 filed by AngioDynamics Inc.S-8 - ANGIODYNAMICS INC (0001275187) (Filer)
- INSIDEREVP and CFO Trowbridge Stephen A bought $9,932 worth of shares (890 units at $11.16), increasing direct ownership by 0.35% to 256,629 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- PRAngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions ListFunction-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care. For the past 25 years, TIME's Best Inventions list has celebrated the most impactful innovat